Somatic cell reprogramming for Parkinson's disease treatment

Abstract

Parkinson's disease (PD) is a neurodegenerative disease characterized by degeneration of dopamine neurons in the substantia nigra pars compacta. The patient exhibits a series of motor symptoms, such as static tremors, which impair their capacity to take care for themselves in daily life. In the late stage, the patient is unable to walk independently and is bedridden for an extended period of time, reducing their quality of life significantly. So far, treatment methods for PD mainly include drug therapy and deep brain stimulation. Pharmacotherapy is aimed at increasing dopamine (DA) levels; however, the treatment effect is more pronounced in the short term, and there is no benefit in improvement in the overall progression of the disease. In recent years, novel therapeutic strategies have been developed, such as cell reprogramming, trying to generate more DA in PD treatment. This review mainly discusses the advantages, methodology, cell origin, transformation efficiency, and practical application shortcomings of cell reprogramming therapy in PD strategy.

Keywords

cell reprogramming / lineage reprogramming / Parkinson's disease

References

[1] Alexander GE. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci. 2004; 6(3): 259-280.

[2] Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013; 62: 132-144.

[3] Gao C, Huang T, Chen R, Yuan Z, Tian Y, Zhang Y. A Han Chinese family with early-onset Parkinson's disease carrying novel frameshift mutation and compound heterozygous mutation of PRKN appearing incompatible with MDS clinical diagnostic criteria. Front Neurol. 2020; 11:582323.

[4] Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease: MDS-PD clinical diagnostic criteria. Mov Disorders. 2015; 30(12): 1591-1601.

[5] Yi S, Wang L, Wang H, Ho MS, Zhang S. Pathogenesis of alpha-synuclein in Parkinson's disease: from a neuron-glia crosstalk perspective. Int J Mol Sci. 2022; 23(23):14753.

[6] Navaratnam P, Arcona S, Friedman HS, Leoni M, Sasane R. Levodopa treatment patterns in Parkinson's disease: a retrospective chart review. Clin Parkinsonism Relat Disorders. 2022; 6:100135.

[7] Pak ME, Ahn SM, Jung DH, et al. Electroacupuncture therapy ameliorates motor dysfunction via brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. J Gerontol A Biol Sci Med Sci. 2020; 75(4): 712-721.

[8] Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990; 247(4942): 574-577.

[9] Man JHK, Groenink L, Caiazzo M. Cell reprogramming approaches in gene- and cell-based therapies for Parkinson's disease. J Control Release. 2018; 286: 114-124.

[10] Zheng X, Han D, Liu W, et al. Human iPSC-derived midbrain organoids functionally integrate into striatum circuits and restore motor function in a mouse model of Parkinson's disease. Theranostics. 2023; 13(8): 2673-2692.

[11] Yeap YJ, Teddy TJW, Lee MJ, Goh M, Lim KL. From 2D to 3D: development of monolayer dopaminergic neuronal and midbrain organoid cultures for Parkinson's disease modeling and regenerative therapy. Int J Mol Sci. 2023; 24(3):2523.

[12] Gurdon JB. Adult frogs derived from the nuclei of single somatic cells. Dev Biol. 1962; 4: 256-273.

[13] Gurdon JB. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol. 1962; 10: 622-640.

[14] Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987; 51(6): 987-1000.

[15] Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature Biotechnol. 2009; 27(3): 275-280.

[16] Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci. 2004; 101(34): 12543-12548.

[17] Stathakos P, Jiménez-Moreno N, Crompton LA, et al. A monolayer hiPSC culture system for autophagy/mitophagy studies in human dopaminergic neurons. Autophagy. 2021; 17(4): 855-871.

[18] Ng YH, Chanda S, Janas JA, et al. Efficient generation of dopaminergic induced neuronal cells with midbrain characteristics. Stem Cell Rep. 2021; 16(7): 1763-1776.

[19] Stoddard-Bennett T, Pera R. Stem cell therapy for Parkinson's disease: safety and modeling. Neural Regen Res. 2020; 15(1): 36-40.

[20] Hallett PJ, Deleidi M, Astradsson A, et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell. 2015; 16(3): 269-274.

[21] Song B, Cha Y, Ko S, et al. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest. 2020; 130(2): 904-920.

[22] Doi D, Magotani H, Kikuchi T, et al. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. Nat Commun. 2020; 11(1): 3369.

[23] Tao Y, Vermilyea SC, Zammit M, et al. Autologous transplant therapy alleviates motor and depressive behaviors in Parkinsonian monkeys. Nat Med. 2021; 27(4): 632-639.

[24] Kikuchi T, Morizane A, Doi D, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature 30 2017; 548(7669): 592-596.

[25] Takahashi J. Preparing for first human trial of induced pluripotent stem cell-derived cells for Parkinson's disease: an interview with Jun Takahashi. Regener Med. 2019; 14(2): 93-95.

[26] Morizane A, Kikuchi T, Hayashi T, et al. MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun. 2017; 8(1): 385.

[27] Wang YK, Zhu WW, Wu MH, et al. Human clinical-grade parthenogenetic ESC-derived dopaminergic neurons recover locomotive defects of nonhuman primate models of Parkinson's disease. Stem Cell Rep. 2018; 11(1): 171-182.

[28] Tofoli FA, Semeano ATS, Oliveira-Giacomelli A, et al. Midbrain dopaminergic neurons differentiated from human-induced pluripotent stem cells. Methods Mol Biol. 2019; 1919: 97-118.

[29] Jönsson ME, Ono Y, Björklund A, Thompson LH. Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis. Exp Neurol. 2009; 219(1): 341-354.

[30] Sundberg M, Bogetofte H, Lawson T, et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013; 31(8): 1548-1562.

[31] Doi D, Samata B, Katsukawa M, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Rep. 2014; 2(3): 337-350.

[32] Fathi A, Mirzaei M, Dolatyar B, et al. Discovery of novel cell surface markers for purification of embryonic dopamine progenitors for transplantation in Parkinson's disease animal models. Mol Cell Proteomics. 2018; 17(9): 1670-1684.

[33] Ogura A, Morizane A, Nakajima Y, Miyamoto S, Takahashi J. γ-Secretase inhibitors prevent overgrowth of transplanted neural progenitors derived from human-induced pluripotent stem cells. Stem Cells Dev. 2013; 22(3): 374-382.

[34] de Luzy IR, Pavan C, Moriarty N, et al. Identifying the optimal developmental age of human pluripotent stem cell-derived midbrain dopaminergic progenitors for transplantation in a rodent model of Parkinson's disease. Exp Neurol. 2022; 358:114219.

[35] de Luzy IR, Law KCL, Moriarty N, et al. Human stem cells harboring a suicide gene improve the safety and standardisation of neural transplants in Parkinsonian rats. Nat Commun. 2021; 12(1): 3275.

[36] Sheikh S, Ernst D, Keating A. Prodrugs and prodrug-activated systems in gene therapy. Mol Ther. 2021; 29(5): 1716-1728.

[37] Hiller BM, Marmion DJ, Gross RM, et al. Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in vivo. Stem Cells Transl Med. 2021; 10(2): 278-290.

[38] Katsukawa M, Nakajima Y, Fukumoto A, Doi D, Takahashi J. Fail-safe therapy by gamma-ray irradiation against tumor formation by human-induced pluripotent stem cell-derived neural progenitors. Stem Cells Dev. 2016; 25(11): 815-825.

[39] Paszkiewicz PJ, Fräßle SP, Srivastava S, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016; 126(11): 4262-4272.

[40] Fujita Y, Hirosawa M, Hayashi K, et al. A versatile and robust cell purification system with an RNA-only circuit composed of microRNA-responsive ON and OFF switches. Sci Adv. 2022; 8(1):eabj1793.

[41] Hiramatsu S, Morizane A, Kikuchi T, Doi D, Yoshida K, Takahashi J. Cryopreservation of induced pluripotent stem cell-derived dopaminergic neurospheres for clinical application. J Parkinson's Dis. 2022; 12(3): 871-884.

[42] Nolbrant S, Heuer A, Parmar M, Kirkeby A. Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. Nat Protoc. 2017; 12(9): 1962-1979.

[43] Brot S, Thamrin NP, Bonnet ML, et al. Long-term evaluation of intranigral transplantation of human iPSC-derived dopamine neurons in a Parkinson's disease mouse model. Cells. 2022; 11(10):1596.

[44] Moriarty N, Kauhausen JA, Pavan C, et al. Understanding the influence of target acquisition on survival, integration, and phenotypic maturation of dopamine neurons within stem cell-derived neural grafts in a Parkinson's disease model. J Neurosci. 2022; 42(25): 4995-5006.

[45] Kim J, Jeon J, Song B, et al. Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells. Nat Protoc. 2022; 17(3): 890-909.

[46] Sánchez-Danés A, Consiglio A, Richaud Y, et al. Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. Hum Gene Ther. 2012; 23(1): 56-69.

[47] Elabi OF, Pass R, Sormonta I, et al. Human embryonic stem cell-derived dopaminergic grafts alleviate L-DOPA induced dyskinesia. J Parkinson's Dis. 2022; 12(6): 1881-1896.

[48] Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010; 463(7284): 1035-1041.

[49] Pfisterer U, Kirkeby A, Torper O, et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci. 2011; 108(25): 10343-10348.

[50] Caiazzo M, Dell'Anno MT, Dvoretskova E, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature. 2011; 476(7359): 224-227.

[51] Han F, Liu Y, Huang J, Zhang X, Wei C. Current approaches and molecular mechanisms for directly reprogramming fibroblasts into neurons and dopamine neurons. Front Aging Neurosci. 2021; 13:738529.

[52] Liu X, Li F, Stubblefield EA, et al. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Res. 2012; 22(2): 321-332.

[53] He M, Zhang H, Li Y, et al. Direct and selective lineage conversion of human fibroblasts to dopaminergic precursors. Neurosci Lett. 2019; 699: 16-23.

[54] Tian C, Li Y, Huang Y, et al. Selective generation of dopaminergic precursors from mouse fibroblasts by direct lineage conversion. Sci Rep. 2015; 5:12622.

[55] Addis RC, Hsu FC, Wright RL, Dichter MA, Coulter DA, Gearhart JD. Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector. PLoS One. 2011; 6(12):e28719.

[56] Qin H, Zhao AD, Sun ML, Ma K, Fu XB. Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and protein factors. Mil Med Res. 2020; 7(1): 52.

[57] Wang Y, Yang H, Yang Q, et al. Chemical conversion of mouse fibroblasts into functional dopaminergic neurons. Exp Cell Res. 2016; 347(2): 283-292.

[58] Park H, Kim H, Yoo J, et al. Homogeneous generation of iDA neurons with high similarity to bona fide DA neurons using a drug inducible system. Biomaterials. Dec 2015; 72: 152-162.

[59] De Gregorio R, Pulcrano S, De Sanctis C, et al. miR-34b/c regulates Wnt1 and enhances mesencephalic dopaminergic neuron differentiation. Stem Cell Reports. Apr 10 2018; 10(4): 1237-1250.

[60] Pascale E, Caiazza C, Paladino M, Parisi S, Passaro F, Caiazzo M. MicroRNA roles in cell reprogramming mechanisms. Cells. 2022; 11(6):940.

[61] Yoo J, Noh M, Kim H, Jeon NL, Kim BS, Kim J. Nanogrooved substrate promotes direct lineage reprogramming of fibroblasts to functional induced dopaminergic neurons. Biomaterials. 2015; 45: 36-45.

[62] Yoo J, Lee E, Kim HY, et al. Electromagnetized gold nanoparticles mediate direct lineage reprogramming into induced dopamine neurons in vivo for Parkinson's disease therapy. Nat Nanotechnol. 2017; 12(10): 1006-1014.

[63] Lim MS, Ko SH, Kim MS, et al. Hybrid nanofiber scaffold-based direct conversion of neural precursor cells/dopamine neurons. Int J Stem Cells. 2019; 12(2): 340-346.

[64] Kim J, Su SC, Wang H, et al. Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell. 2011; 9(5): 413-419.

[65] Kim HS, Kim J, Jo Y, Jeon D, Cho YS. Direct lineage reprogramming of mouse fibroblasts to functional midbrain dopaminergic neuronal progenitors. Stem Cell Res. 2014; 12(1): 60-68.

[66] Oh S, Park H, Hwang I, et al. Efficient reprogramming of mouse fibroblasts to neuronal cells including dopaminergic neurons. Scientific World J. 2014; 2014:957548.

[67] Jiang H, Xu Z, Zhong P, et al. Cell cycle and p53 gate the direct conversion of human fibroblasts to dopaminergic neurons. Nat Commun. 2015; 6:10100.

[68] Rivetti di Val Cervo P, Romanov RA, Spigolon G, et al. Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model. Nature Biotechnol. 2017; 35(5): 444-452.

[69] Playne R, Jones K, Connor B. Generation of dopamine neuronal-like cells from induced neural precursors derived from adult human cells by non-viral expression of lineage factors. J Stem Cells Regener Med. 2018; 14(1): 34-44.

[70] Raina A, Mahajani S, Bähr M, Kügler S. Neuronal trans-differentiation by transcription factors Ascl1 and Nurr1: induction of a dopaminergic neurotransmitter phenotype in cortical GABAergic neurons. Mol Neurobiol. 2020; 57(1): 249-260.

[71] Qian H, Kang X, Hu J, et al. Reversing a model of Parkinson's disease with in situ converted nigral neurons. Nature. 2020; 582(7813): 550-556.

[72] Lee S, Shim HS, Park HJ, et al. Elongated nanoporous Au networks improve somatic cell direct conversion into induced dopaminergic neurons for Parkinson's disease therapy. Acta Biomater. 2022; 151: 561-575.

[73] Drouin-Ouellet J, Legault EM, Nilsson F, et al. Age-related pathological impairments in directly reprogrammed dopaminergic neurons derived from patients with idiopathic Parkinson's disease. Stem Cell Rep. 2022; 17(10): 2203-2219.

[74] Ahmad I, Zhao X, Parameswaran S, et al. Direct differentiation of adult ocular progenitors into striatal dopaminergic neurons. Int J Stem Cells. 2015; 8(1): 106-114.

[75] Yang H, Hao D, Liu C, et al. Generation of functional dopaminergic neurons from human spermatogonial stem cells to rescue Parkinsonian phenotypes. Stem Cell Res Ther. 2019; 10(1): 195.

[76] Yuan Y, Tang X, Bai YF, et al. Dopaminergic precursors differentiated from human blood-derived induced neural stem cells improve symptoms of a mouse Parkinson's disease model. Theranostics. 2018; 8(17): 4679-4694.

[77] Niknejad H, Deihim T, Ahmadiani A, Jorjani M, Peirovi H. Permanent expression of midbrain dopaminergic neurons traits in differentiated amniotic epithelial cells. Neurosci Lett. 2012; 506(1): 22-27.

[78] Yamane M, Takaoka N, Obara K, et al. Hair-follicle-associated pluripotent (HAP) stem cells can extensively differentiate to tyrosine-hydroxylase-expressing dopamine-secreting neurons. Cells. 2021; 10(4):864.

[79] Vukicevic V, Schmid J, Hermann A, et al. Differentiation of chromaffin progenitor cells to dopaminergic neurons. Cell Transplant. 2012; 21(11): 2471-2486.

[80] Jiang P, Huang P, Yen SH, Zubair AC, Dickson DW. Genetic modification of H2AX renders mesenchymal stromal cell-derived dopamine neurons more resistant to DNA damage and subsequent apoptosis. Cytotherapy. 2016; 18(12): 1483-1492.

[81] Shall G, Menosky M, Decker S, et al. Effects of passage number and differentiation protocol on the generation of dopaminergic neurons from rat bone marrow-derived mesenchymal stem cells. Int J Mol Sci. 2018; 19(3):720.

[82] Chlebanowska P, Sułkowski M, Skrzypek K, et al. Origin of the induced pluripotent stem cells affects their differentiation into dopaminergic neurons. Int J Mol Sci. 2020; 21(16):5705.

[83] Della Valle F, Thimma MP, Caiazzo M, et al. Transdifferentiation of mouse embryonic fibroblasts into dopaminergic neurons reactivates LINE-1 repetitive elements. Stem Cell Rep. 2020; 14(1): 60-74.

[84] Yu X, Nagai J, Khakh BS. Improved tools to study astrocytes. Nat Rev Neurosci. 2020; 21(3): 121-138.

[85] Jiang MQ, Yu SP, Wei ZZ, et al. Conversion of reactive astrocytes to induced neurons enhances neuronal repair and functional recovery after ischemic stroke. Front Aging Neurosci. 2021; 13:612856.

[86] L'Episcopo F, Tirolo C, Peruzzotti-Jametti L, et al. Neural stem cell grafts promote astroglia-driven neurorestoration in the aged parkinsonian brain via Wnt/β-catenin signaling. Stem Cells. 2018; 36(8): 1179-1197.

[87] Pulcrano S, De Gregorio R, De Sanctis C, et al. Lmx1a-dependent activation of miR-204/211 controls the timing of Nurr1-mediated dopaminergic differentiation. Int J Mol Sci. 2022; 23(13):6961.

[88] Giehrl-Schwab J, Giesert F, Rauser B, et al. Parkinson's disease motor symptoms rescue by CRISPRa-reprogramming astrocytes into GABAergic neurons. EMBO Mol Med. 2022; 14(5):e14797.

[89] Sagal J, Zhan X, Xu J, et al. Proneural transcription factor Atoh1 drives highly efficient differentiation of human pluripotent stem cells into dopaminergic neurons. Stem Cells Transl Med. 2014; 3(8): 888-898.

[90] Xue Y, Zhan X, Sun S, et al. Synthetic mRNAs drive highly efficient iPS cell differentiation to dopaminergic neurons. Stem Cells Transl Med. 2019; 8(2): 112-123.

[91] Liu L, Michowski W, Kolodziejczyk A, Sicinski P. The cell cycle in stem cell proliferation, pluripotency and differentiation. Nature Cell Biol. 2019; 21(9): 1060-1067.

[92] Wang XQ, Lo CM, Chen L, Ngan ESW, Xu A, Poon RY. CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency. Cell Death Differ. 2017; 24(1): 38-48.

[93] Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009; 460(7259): 1132-1135.

[94] Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009; 460(7259): 1140-1144.

[95] Liu X, Huang Q, Li F, Li CY. Enhancing the efficiency of direct reprogramming of human primary fibroblasts into dopaminergic neuron-like cells through p53 suppression. Sci China Life Sci. 2014; 57(9): 867-875.

[96] Chen K, Long Q, Wang T, et al. Gadd45a is a heterochromatin relaxer that enhances iPS cell generation. EMBO Rep. 2016; 17(11): 1641-1656.

[97] Chen K, Long Q, Xing G, et al. Heterochromatin loosening by the Oct4 linker region facilitates Klf4 binding and iPSC reprogramming. EMBO J. 2020; 39(1):e99165.

[98] Dalby MJ, Gadegaard N, Tare R, et al. The control of human mesenchymal cell differentiation using nanoscale symmetry and disorder. Nat Mater. 2007; 6(12): 997-1003.

[99] Guilak F, Cohen DM, Estes BT, Gimble JM, Liedtke W, Chen CS. Control of stem cell fate by physical interactions with the extracellular matrix. Cell Stem Cell. 2009; 5(1): 17-26.

[100] Kulangara K, Adler AF, Wang H, et al. The effect of substrate topography on direct reprogramming of fibroblasts to induced neurons. Biomaterials. 2014; 35(20): 5327-5336.

[101] I. Schwerdt J, F. Goya G, Pilar Calatayud M, B. Herenu C, C. Reggiani P, G. Goya R. Magnetic field-assisted gene delivery: achievements and therapeutic potential. Curr Gene Ther. 2012; 12(2): 116-126.

[102] Schweitzer JS, Song B, Herrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. N Engl J Med. 2020; 382(20): 1926-1932.

[103] Gudenschwager C, Chavez I, Cardenas C, Gonzalez-Billault C. Directly reprogrammed human neurons to understand age-related energy metabolism impairment and mitochondrial dysfunction in healthy aging and neurodegeneration. Oxid Med Cell Longevity. 2021; 2021:5586052.

[104] Pacelli C, Giguère N, Bourque MJ, Lévesque M, Slack RS, Trudeau LÉ. Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons. Curr Biol. 21 2015; 25(18): 2349-2360.

[105] Huh CJ, Zhang B, Victor MB, et al. Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. eLife. 2016; 5:e18648.

[106] Kim Y, Zheng X, Ansari Z, et al. Mitochondrial aging defects emerge in directly reprogrammed human neurons due to their metabolic profile. Cell Rep. 2018; 23(9): 2550-2558.

[107] Mertens J, Paquola ACM, Ku M, et al. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell. 2015; 17(6): 705-718.

[108] Aversano S, Caiazza C, Caiazzo M. Induced pluripotent stem cell-derived and directly reprogrammed neurons to study neurodegenerative diseases: the impact of aging signatures. Front Aging Neurosci. 2022; 14:1069482.

[109] Moriarty N, Gantner CW, Hunt CPJ, et al. A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells. Cell Stem Cell. 2022; 29(3): 434-448.e5.

RIGHTS & PERMISSIONS

2025 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University and Wiley-VCH GmbH.